CureVac Commences Global Pivotal Phase 2b/3 Trial
Study expected to enroll more than 35,000 participants, focusing on Europe and Latin America
15-Dec-2020 -
CureVac N.V. announced that it has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adults at a ...
coronaviruses
Covid-19
CureVac
+4